All In Biotech

Drug Trial Radar · NCT00313820

Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain

A 13-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (150-600 Mg/Day) Using A Flexible Dosing Schedule In The Treatment Of Subjects With Central Post-Stroke Pain (CPSP)

Last checked: Nov 20, 2026Latest source record: Feb 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

Aug 2006

Primary completion

Sep 2008

Study completion Sep 2008

Sponsor

Sponsor type
Industry
First posted
Apr 12, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and Safety of flexibly dosed pregabalin compared to placebo among subjects with central post stroke pain (CPSP)

Conditions

  • Central Neuropathic Pain

Interventions

  • PregabalinDrug

    Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.

  • PlaceboDrug

    Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Pain Score at Endpoint as Measured by Daily Pain Rating Scale (DPRS)Time frame: Up to Week 12

Locations

33 sites in 11 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Darlinghurst, New South Wales, Australia

  • Pfizer Investigational Site

    East Gosford, New South Wales, Australia

  • Pfizer Investigational Site

    St Leonards, New South Wales, Australia

  • Pfizer Investigational Site

    Warrawong, New South Wales, Australia

  • Pfizer Investigational Site

    Herston, Queensland, Australia

  • Pfizer Investigational Site

    Footscray, Victoria, Australia

  • Pfizer Investigational Site

    Perth, Western Australia, Australia

  • Pfizer Investigational Site

    Beijing, China

  • Pfizer Investigational Site

    Beijing, China

  • Pfizer Investigational Site

    Guangzhou, China

  • Pfizer Investigational Site

    Shanghai, China

  • Pfizer Investigational Site

    Shanghai, China

  • Pfizer Investigational Site

    New Territories, Hong Kong

  • Pfizer Investigational Site

    Bangalore, India

  • Pfizer Investigational Site

    Bangalore, India

  • Pfizer Investigational Site

    Chennai, India

  • Pfizer Investigational Site

    Lucknow, India

  • Pfizer Investigational Site

    New Delhi, India

  • Pfizer Investigational Site

    Jakarta, Indonesia

  • Pfizer Investigational Site

    Surabaya, Indonesia

  • Pfizer Investigational Site

    George Town, Malaysia

  • Pfizer Investigational Site

    Kuala Lumpur, Malaysia

  • Pfizer Investigational Site

    Kuala Selangor, Malaysia

  • Pfizer Investigational Site

    Karachi, Pakistan

  • Pfizer Investigational Site

    Karachi, Sindh, Pakistan

  • Pfizer Investigational Site

    Manila, Philippines

  • Pfizer Investigational Site

    Manila, Philippines

  • Pfizer Investigational Site

    Seoul, South Korea

  • Pfizer Investigational Site

    Taichung, Taiwan

  • Pfizer Investigational Site

    Taipei, Taiwan

  • Pfizer Investigational Site

    Gueishan Shiang, Taoyuan Hsien, Taiwan

  • Pfizer Investigational Site

    Bangkok, Thailand

  • Pfizer Investigational Site

    Ratchatewee, Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.